Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262206 · ClinicalTrials.gov registry record · Phase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
A Phase 4 study of Cardiovascular Diseases and Dementia, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20,000
- Enrollment target
- 20
- Study locations
NCT04262206 is a Phase 4 study of Cardiovascular Diseases and Dementia that is actively recruiting participants, run by Duke University. The registered enrollment target is 20,000 participants, below the 26,908-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04262206, a Phase 4 study of Cardiovascular Diseases and Dementia, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Conditions Studied
Interventions
- DRUG Atorvastatin 40 Mg Oral Tablet
- DRUG Placebo oral tablet
Study Locations (20)
California
- Fresno VA Medical Center - Fresno
- Long Beach VA Medical Center - Long Beach
- Cedars-Sinai Medical Center - Los Angeles
- VA Greater Los Angeles - Los Angeles
- VA Palo Alto Healthcare System - Palo Alto
- VA San Diego Medical Center - San Diego
Florida
- Bay Pines VA - Bay Pines
- Gainesville VA Medical Center - Gainesville
- University of Florida - Gainesville
- University of Florida - Jacksonville
- Miami VA Medical Center - Miami
- University of Miami - Miami
Alabama
- University of Alabama at Birmingham - Birmingham
- Birmingham VA - Birmingham
Arkansas
- Little Rock VA Medical Center - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale University - New Haven
- VA Connecticut Healthcare System - West Haven
Arizona
- Southern Arizona VA Health Care System - Tucson - Tucson
Georgia
- Atlanta VA Medical Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04262206
The ClinicalTrials.gov registry entry for NCT04262206 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,908-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (26% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin 40 Mg Oral Tablet is the first listed.
NCT04262206 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT04262206 about?
NCT04262206 is a clinical study titled "Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults". PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the b...
What is the current status of trial NCT04262206?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20,000 participants. The study started on 2020-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04262206 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Dementia, Cognitive Impairment, Mild.
What interventions are being tested in trial NCT04262206?
The interventions under investigation include: Atorvastatin 40 Mg Oral Tablet (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04262206?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262206 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.